The devices described herein are constructed in wire form where the wires diverge from a main bundle to form a variety of shapes that form a composite device. The benefit of such a diverging wire construction is that the composite complex device can be of a “joint-less” construction. Such devices have applicability through out the body, including clearing of blockages within body lumens, such as the vasculature, by providing a capturing portion that can envelop the obstruction to address the frictional resistance between the obstruction and body lumen prior to attempting to translate and/or mobilize the obstruction within the body lumen. In addition, the devices described below include features that prevent unwanted and premature mobilization of the obstruction when removing the obstruction through tortuous anatomy.
Many medical device applications require advancement of device in a reduced profile to a remote site within the body, where on reaching a target site the device assumes or is deployed into a relatively larger profile. Applications in the cerebral vasculature are one such example of medical procedures where a catheter advances from a remote part of the body (typically a leg) through the vasculature and into the cerebral region of the vasculature to deploy a device. Accordingly, the deployed devices must be capable of achieving a larger profile while being able to fit within a small catheter or microcatheter. In addition, the degree to which a physician is limited in accessing remote regions of the cerebral vasculature is directly related to the limited ability of the device to constrain into a reduced profile for delivery.
Treatment of ischemic stroke is one such area where a need remains to deliver a device in a reduced profile and deploy the device to ultimately remove a blockage in an artery leading to the brain. Left untreated, the blockage causes a lack of supply of oxygen and nutrients to the brain tissue. The brain relies on its arteries to supply oxygenated blood from the heart and lungs. The blood returning from the brain carries carbon dioxide and cellular waste. Blockages that interfere with this supply eventually cause the brain tissue to stop functioning. If the disruption in supply occurs for a sufficient amount of time, the continued lack of nutrients and oxygen causes irreversible cell death (infarction). Accordingly, immediate medical treatment of an ischemic stroke is critical for the recovery of a patient.
Naturally, areas outside of ischemic stroke applications can also benefit from devices that can assume a profile for ultimate delivery to remote regions of the body.
Accordingly, a need remains for devices that can assume deployed configurations and are fabricated to eliminate or reduce the number of joints and/or connection points in the device. Elimination of the joints also allows the device to have a compact and smooth configuration making it easier for delivery through a microcatheter, and leads to a safer device less prone to breaking or embolizing. Another need remains for a device that can translate over and securely remove the obstruction from tortuous anatomy.
The examples discussed herein show the inventive device in a form that is suitable to retrieve obstructions or clots within the vasculature. The term obstructions may include blood clot, plaque, cholesterol, thrombus, naturally occurring foreign bodies (i.e., a part of the body that is lodged within the lumen), a non-naturally occurring foreign body (i.e., a portion of a medical device or other non-naturally occurring substance lodged within the lumen.) However, the devices are not limited to such applications and can apply to any number of medical applications where elimination or reduction of the number of connection points is desired.
In one variation of the devices described herein, the device comprises a main bundle or group of wires that diverge to form a device having various shapes but few or no connections points or joints (where fabrication of such a construction is referred to as “jointless”). Clearly, the inventive devices described herein are not limited to such a jointless construction. Additional variation includes one or more leading wires that are attached to a capturing portion as described below.
In one variation, the device includes a main bundle comprising one or a group of wires. The device also includes a capturing portion formed by the wires or wire of the main bundle. The capturing portion includes a cavity or space that is able to surround the obstruction. Accordingly, the capturing portion includes an open proximal end, a permeable distal end, and a capturing surface extending therebetween. The permeable distal end should be sufficiently permeable to allow blood to flow but have sufficient surface area to prevent escape of the obstruction or to prevent particles such as pieces of clot or emboli that would otherwise cause a complication if such pieces migrate through the body. In some variations of the device, the capturing portion is formed from the group of wires such that the group of wires diverges from the second end of the main bundle to form the permeable distal end, the group of wires extend back in a proximal direction to form the capturing surface and open proximal end about the main bundle, such that articulation of the capturing portion relative to the main bundle does not cause the open proximal end to reduce in size. Although some closing of the open proximal end can occur, it will not be sufficient to interfere with the obstruction as the capturing portion moves over the obstruction. In some variations, the permeable end may be the distal end or be towards the distal end (meaning anywhere past a proximal end). The terms distal and proximal are relative to the physician (e.g., the distal end is the farthest end from the catheter/physician).
The devices of the present invention typically include a main bundle from which the wires extend. In most case, the main bundle extends for a length sufficient to withdraw the device from a body of a patient. Accordingly, in such cases, the main bundle shall extend through the length of a catheter. In alternate constructions, the main bundle may be affixed to a single wire or member. In such cases, a main bundle does not extend from the capturing portion to the exterior of the patient. Instead, a single wire extends to the operator interface of the device where the wire is affixed to a main bundle.
Devices of the present invention can incorporate any number of wires of different characteristics including, but not limited to, materials, shapes, sizes and/or diameters. Clearly, the number of permutations of device configurations is significant. Providing devices with such a composite construction allows for the manipulation of the device's properties to suite the intended application.
In an additional variation, the surface of the capturing portion can include a wire frame structure, a mesh, a single wound wire, a film, a membrane, a polymer covering, and a plurality of crossing wires or a heterogeneous mixing of these. In additional variations, a section of the capturing portion can include wires, while another section of the capturing portion can include a film. Clearly, any number of permutations is within the scope of this disclosure. In any case, the capturing surface should prevent the obstruction from escaping as the device is removed from the body. Clearly, the capturing surface can comprise any number of shapes or configurations.
As noted herein, the joint-less construction improves the flexibility and strength of the device by eliminating joints, connection points, or other attachment points. In addition, the joint-less construction improves the ability of the device to be delivered through a small microcatheter. As a result, the device and microcatheter are able to access remote regions of the vasculature.
The devices may be fabricated to be self-expanding upon deployment from a catheter. Alternatively, the devices can be constructed from shape-memory alloys such that they automatically deploy upon reaching a pre-determined transition temperature.
The devices of the present invention may also include features to prevent migration of the obstruction as the capturing portion encapsulates the obstruction. For example, a proximal foot (such as region of increased surface area) can be located on or in the catheter. In another variation, an additional capture portion is located on the catheter where the proximal end of this capture is a mesh, a single wound wire, a film, a membrane, a polymer covering, or a plurality of crossing wires affixed to or in the catheter. Accordingly, the capturing portions both envelope or surround the obstruction as they are moved together. As noted below, additional variations may allow for temporarily locking of the two capturing portions together for increase effectiveness in removing the obstruction from the body.
The operation of the devices and method described herein secure the obstruction, overcome the friction forces acting on the obstruction, and then remove the obstruction from the anatomy without losing or fractionating the obstruction. In one variation of the invention, this is accomplished by the obstruction removal device interacting with the obstruction in the following manner: (1) a catheter passes distal to the obstruction by passing either through the obstruction and/or between the obstruction and the vascular wall; (2) a first capturing portion is deployed distally to the obstruction and the catheter is withdrawn proximal to the obstruction; (3) the capturing portion is then translated over the obstruction by withdrawing the main bundle. Since the main bundle is affixed to a distal end of the capturing portion, misalignment between the bundle and the capturing portion does not cause distortion of the open proximal end. Since the open proximal end remains expanded against the lumen wall, the capturing portion can then be advanced over the obstruction.
The method and systems may also include the use of an additional capturing portion having an open distal end. This configuration allows the first capturing portion and second capturing portion to envelop or ensnare the obstruction from both the proximal and distal sides. Additional variations even allow for temporarily locking the two capturing portions together. Such a feature increases the ability to remove the obstruction from the body
It should be noted that reference to surrounding, capturing or securing the obstruction includes partially and/or fully surrounding, engulfing, encapsulating, and/or securing the obstruction. In any case, a portion of the device engages the obstruction prior to translation of the obstruction within the lumen.
It should be noted that in some variations of the invention, all or some of the device can be designed to increase their ability to adhere to the obstruction. For example, the wires may be coupled to an energy source (e.g., RF, ultrasonic, or thermal energy) to “weld” to the obstruction. Application of energy to the device can allow the surrounding portion to deform into the obstruction and “embed” within the obstruction. Alternatively, the device can impart a positive charge to the obstruction to partially liquefy the obstruction sufficiently to allow for easier removal. In another variation, a negative charge could be applied to further build thrombus and nest the device for better pulling force. The wires can be made stickier by use of a hydrophilic substance(s), or by chemicals that would generate a chemical bond to the surface of the obstruction. Alternatively, the filaments may reduce the temperature of the obstruction to congeal or adhere to the obstruction.
Additional devices and methods for treating ischemic stroke are discussed in commonly assigned U.S. patent application Ser. No. 11/671,450 filed Feb. 5, 2007; Ser. No. 11/684,521 filed Mar. 9, 2007; Ser. No. 11/684,535 filed Mar. 9, 2007; Ser. No. 11/684,541 filed Mar. 9, 2007; Ser. No. 11/684,546 filed Mar. 9, 2007; Ser. No. 11/684,982 filed Mar. 12, 2007, Ser. No. 11/736,526 filed Apr. 17, 2007 and Ser. No. 11/736,537 filed Apr. 17, 2007; the entirety of each of which is incorporated by reference. The principles of the invention as discussed herein may be applied to the above referenced cases to produce devices useful in treating ischemic stroke. In other words, the wire-shaped construction of devices according to present invention may assume the shapes disclosed in the above-referenced cases when such a combination is not inconsistent with the features described herein.
Each of the following figures diagrammatically illustrates aspects of the invention. Variation of the invention from the aspects shown in the figures is contemplated.
It is understood that the examples below discuss uses in the cerebral vasculature (namely the arteries). However, unless specifically noted, variations of the device and method are not limited to use in the cerebral vasculature. Instead, the invention may have applicability in various parts of the body. Moreover, the invention may be used in various procedures where the benefits of the method and/or device are desired.
It is noted that any number of catheters or microcatheters maybe used to locate the catheter/microcatheter 12 carrying the obstruction removal device 200 at the desired target site. Such techniques are well understood standard interventional catheterization techniques. Furthermore, the catheter 12 may be coupled to auxiliary or support components 14, 16 (e.g., energy controllers, power supplies, actuators for movement of the device(s), vacuum sources, inflation sources, sources for therapeutic substances, pressure monitoring, flow monitoring, various bio-chemical sensors, bio-chemical substance, etc.) Again, such components are within the scope of the system 10 described herein.
In addition, devices of the present invention may be packaged in kits including the components discussed above along with guiding catheters, various devices that assist in the stabilization or removal of the obstruction (e.g., proximal-assist devices that holds the proximal end of the obstruction in place preventing it from straying during removal or assisting in the removal of the obstruction), balloon-tipped guide catheters, dilators, etc.
The individual wires 204 themselves may be comprised of a number of different “micro” filaments, wires, or a single type of wire. Variations of the wires 204 are discussed in detail below; however, the wires 204 can be strands, filaments, or any similar structure that is able to be joined to form the device. The bundle 202 may be braided, wrapped, twisted, or joined in any manner such that they do not separate or become unbundled except where desired. For example, wires in any section of the device 200 can be bonded together (e.g., with epoxy, a polymeric coating, weld, solder, and/or adhesive, etc.) to prevent the wires from separating during deformation of the device as it deploys or removes the obstruction. In addition, the main bundle 202 can incorporate any number of features to assist in orienting the device 200 within the body passage. For example, the main bundle 202 can include a pre-set bend that would bias the capturing portion in a desired orientation upon deployment as discussed below (
The device 200 also includes a capturing portion 226. This capturing portion 226 may comprise such constructional designs as a basket, a filter, a bag, a coil, a helical wire structure, a mesh, a single wound wire, a film, a membrane, a polymer covering, or a plurality of crossing wires. In variations of the device, the capturing portion 226 is sufficiently permeable to allow blood or other fluid flow therethrough. As noted above, capturing portion 226 may be any structure that covers, encapsulates, engulfs, and/or ensnares the obstruction either fully or partially. Accordingly; although the capturing portion 226 is illustrated as a filter/bag, the wires may diverge to form a coil, helical shape, other mesh structure, or any other structure that defines a space that can be translated over the obstruction to ultimately remove the obstruction 2.
The capturing portion 226 includes an open proximal end 228, a permeable distal end 230 and a capturing surface 232 located therebetween. The surface 232 of the capturing portion 226 defines a volume, cavity, or space that is able to cover, encapsulate, envelop, engulf, ensnare and/or surround the obstruction. Generally, the term traversing wire or filament refers to the section of wire 204 that forms the capturing surface 232. Generally, the traversing wires form the capturing surface 232 and then form the open proximal end 228. As discussed herein and illustrated below, the open proximal end 228 expands within the lumen, typically to the lumen walls, so that the obstruction enters the open proximal end 228 as the bundle 202 translates the device 200 proximally. In most devices, the open proximal end 228 is designed to provide a low friction surface so that it translates over the obstruction without moving the obstruction significantly. The capturing surface 232 has an increased frictional surface so that it can capture and ultimately remove the obstruction. The frictional surface can also be described as a coverage density. In essence, as the frictional surface/coverage density increases, there is more “device” surface area to interact with the obstruction. In some variations the capturing surface has an increasing frictional surface between the open proximal end and the permeable distal end.
The permeable distal end 230 is typically sufficiently porous so that fluid or blood may flow through. However, the end 230 is sufficiently closed (or has an increased surface area) so that the obstruction should not escape through the distal end 230 of the device 200. The obstruction becomes ensnared within the capturing portion 226 and is prevented from passing through by the permeable distal end 230.
One important feature of the present devices is that the main bundle 202 and capturing portion 226 can articulate relative to one another without interfering with the size or profile of the open proximal end 228. This feature is described more fully in
Turning now to the construction of the device 200, as shown in
The devices of the present invention can also include additional features to aid in removal of obstructions. For example, as shown in
In additional variations, the main bundle can diverge to form the capturing portion in multiple locations so long as the capturing portion's ability to articulate is not sacrificed. For example, the main bundle can diverge in several locations along the capturing surface (not shown).
In addition to the reinforcement ring 240,
As shown in
Naturally, the divergence of the wires can occur over a length of the capturing portion 226 rather than immediately at the distal end. For example, as show in
The twisting configuration shown in
As show, the device includes mechanical features that assist in removal of the obstruction. These features can be hooks, fibers, barb, or any such structure. For example, such mechanical features are illustrated on
The device may include a number of radiopaque wires, such as gold and platinum for improved visibility under fluoroscopic imaging. In other words, any combination of materials may be incorporated into the device. In addition to the materials, the size of the wires may vary as needed. For example, the diameters of the wires may be the same or may vary as needed.
In addition, the individual wires may have cross-sectional shapes ranging from circular, oval, d-shaped, rectangular shape, etc.
To illustrate one such example, a device can have 8-12 wires made of 0.003″ round superelastic material (e.g., nitinol). The device may additionally have 2-4 wires made from 0.002″ platinum for fluoroscopy. Of the 8-12 nitinol wires, 1-4 of these wires can be made of a larger diameter or different cross-section to increase the overall strength of the device. Finally, a couple of polymer fibers can be added where the fibers have a desired surface property for clot adherence, etc. Such a combination of wires provides a composite device with properties not conventionally possible in view of other formation means (such as laser cutting or etching the shape from a tube or joining materials with welds, etc.). Clearly, any number of permutations is possible given the principles of the invention.
In another example, the device may be fabricated from wires formed from a polymeric material or composite blend of polymeric materials. The polymeric composite can be selected such that it is very floppy until it is exposed to either the body fluids and or some other delivered activator that causes the polymer to further polymerize or stiffen for strength. Various coatings could protect the polymer from further polymerizing before the device is properly placed. The coatings could provide a specific duration for placement (e.g., 5 minutes) after which the covering degrades or is activated with an agent (that doesn't affect the surrounding tissues) allowing the device to increase in stiffness so that it doesn't stretch as the thrombus is pulled out. For example, shape memory polymers would allow the device to increase in stiffness.
In another variation, one or more of the wires used in the device may comprise a Drawn Filled Tube (DFT) such as those provided by Fort Wayne Metals, Fort Wayne, Ind. As shown in
The size of the proximal foot 256 can be adjusted depending on the target site anatomy. For example, a larger surface area can be employed if the target site is within a bifurcation of the body passage. The size of the proximal foot 256 can also be adjustable during the procedure. For example, in the case of a petal/flange 258 configuration, the petals 258 can assume a larger size to initially stabilize the obstruction and then reduce in size to allow the obstruction to be completely engulfed by capturing section 226.
The proximal foot 256 can extend from an interior of the catheter 102, such as from within the internal lumen of the catheter, or from an additional lumen within a wall of the catheter. Alternatively, the proximal foot 256 can be permanently affixed to the catheter 102. In such a case, a separate catheter (without a proximal foot) can be employed to traverse the obstruction for deployment of the device distally to the obstruction. Once the device is deployed, the catheters can be exchanged to provide the proximal foot. In an additional variation, the proximal foot 256 can be affixed to a delivery sheath (as described below) and be collapsed within the catheter, where advancement out of the catheter expands the proximal foot 256 so that it may function as described above.
In any case, the construction of the system 10 shown in
As shown, the proximal end 264 can be compressed using a sheath 106. However, other means of compressing may be employed (e.g., a loop structure, a tube over the sheath, a draw-string configuration, etc.) In use, once the distal capturing portion 200 is deployed distally to the obstruction 2 and the catheter 102 is withdrawn proximal to the obstruction 2, the proximal capturing portion 260 is deployed. As the proximal capturing portion 260 partially (or totally) engulfs the obstruction 2, the physician can collapse or compress the proximal capturing portion 260 to better secure the obstruction within the system 10.
It is noted that any number of shapes, configurations, as well as any number of joined wires may be contemplated to form devices under the present disclosure. However, variations of the invention include selecting a number of wires to produce specific structural properties to the device. For example, the devices can have any number of wires where the limit is determined by the ability to produce a device of a sufficiently small size to access the area containing the obstruction. However, in some cases, it may be desired that wires are chosen to impart specified characteristics. For example, in the illustrated variation, the main bundle may comprise any number of wires that do not diverge to form subsequent shapes in the device. In other words, not all of the wires forming a section are required to diverge to form an adjacent section. Instead, these non-diverging wires may simply “loop” back away from the device. In an additional variation, one or more wires may diverge to form a particular portion of the capturing portion (e.g., the closed end, traversing wires, etc.). Then the wires can loop back to converge again with the main bundle.
Some variations of the device may be placed without an accompanying guidewire. Moreover, the structures discussed herein may be directly incorporated into a guidewire assembly where deployment may require a sheath or other covering to release the components from constraint.
As also shown in the figure, the main bundle 202 and capturing portions become misaligned due to the tortuousity of the anatomy. However, because the capturing portions 226 and 260 are able to pivot or articulate relative to the main bundle 202 and catheter 102 or sheath 106, the open ends are able to remain against the lumen wall. In conventional devices where the open end is attached to either a wire or catheter, when the wire or catheter bends in the anatomy, the forces exerted on the open ends deform or distort the end to assume a reduced profile. Accordingly, the physician may have difficulty in removing an obstruction if the profile of the open end becomes reduced in size. Closing of the open end can also result in vascular damage if the physician applies too much force in translating the device.
Although the illustrated variation shown above comprise open-ended, circular, looped or partial loop shape cross sectional areas, variations of the capturing portions can include any number of shapes. For example, such a shape can include a circle, an arcuate shape, a partial circular shape, a loop, an oval, a square, a rectangle, a polygon, an overlapping loop, a pair of semi-circles, etc.) The various shapes may be heat set to be either self-expanding (i.e., superelastic) or the use of shape memory alloys can allow for the device to assume the particular shape upon reaching a desired transition temperature.
The exemplary shapes discussed above permit the shaped section to adjust in diameter in response to placement in varying diameters of body lumens. It is noted that a device may have different shaped sections on different ends of the device.
While many different shapes are contemplated to be within the scope of this disclosure, the shapes will depend upon the ultimate application of the device. As noted herein, the illustrated examples have particular applicability in retrieving obstructions from the vasculature. Accordingly, for these applications the shaped sections should form a shape so that they can expand against a vessel wall without causing trauma to the vessel. For example, upon release from the catheter, the shaped section can assume their resting shape and expand within the vessel. The resting shape can be constructed to have a size slightly greater than that of the vessel. Sizing the device relative to the target vessel may assist in placing the parts of the device against a vessel.
In an additional aspect, the shaped sections may be designed to have an unconstrained shape that is larger than the intended target vessel or simply different than a cross sectional profile of the intended vessel (i.e., not circular or tubular, but e.g., linear or other different shape). In such an example, as the shaped section is released from the delivery catheter, the shape section attempts to return to the unconstrained shape. In those variations where the unconstrained shape is different from the circular profile of the vessel, the leading wire assumes a shape that accommodates the vessel but is more rigid and stable since its unconstrained shape is entirely different from that of the vessel. In other words, the shaped section continually exerts an outward force on the vessel.
In yet another aspect, the shaped sections shown herein may not necessarily lie in the same plane. Instead, they can be axially spaced by an offset. One benefit of constructing the device to have non-planar shaped section is that the configuration might allow for delivery of the device through a smaller microcatheter because the shaped sections do not interfere with one another when collapsed to fit within the microcatheter.
Another aspect applicable to all variations of the devices is to configure the devices (whether the traversing filament or the surrounding portion) for better adherence to the obstruction. One such mode includes the use of coatings that bond to certain clots (or other materials causing the obstruction.) For example, the wires may be coated with a hydrogel or adhesive that bonds to a thrombus. Accordingly, as the device secures about a clot, the combination of the additive and the mechanical structure of the device may improve the effectiveness of the device in removing the obstruction. Coatings may also be combined with the capturing portions or catheter to improve the ability of the device to encapsulate and remove the obstruction (e.g., a hydrophilic coating).
Such improvements may also be mechanical or structural. Any portion of the capturing portion can have hooks, fibers, or barbs 154 (see e.g.,
In addition to additives, the device can be coupled to an RF or other power source (such as 14 or 16 in
The methods described herein may also include treating the obstruction prior to attempting to remove the obstruction. Such a treatment can include applying a chemical or pharmaceutical agent with the goal of making the occlusion shrink or to make it more rigid for easier removal. Such agents include, but are not limited to chemotherapy drugs, or solutions, a mild formalin, or aldehyde solution.
As for other details of the present invention, materials and manufacturing techniques may be employed as within the level of those with skill in the relevant art. The same may hold true with respect to method-based aspects of the invention in terms of additional acts that are commonly or logically employed. In addition, though the invention has been described in reference to several examples, optionally incorporating various features, the invention is not to be limited to that which is described or indicated as contemplated with respect to each variation of the invention.
It is important to note that where possible, aspects of the various described embodiments, or the embodiments themselves can be combined. Where such combinations are intended to be within the scope of this disclosure.
Various changes may be made to the invention described and equivalents (whether recited herein or not included for the sake of some brevity) may be substituted without departing from the true spirit and scope of the invention. Also, any optional feature of the inventive variations may be set forth and claimed independently, or in combination with any one or more of the features described herein. Accordingly, the invention contemplates combinations of various aspects of the embodiments or combinations of the embodiments themselves, where possible. Reference to a singular item, includes the possibility that there are plural of the same items present. More specifically, as used herein and in the appended claims, the singular forms “a,” “and,” “said,” and “the” include plural references unless the context clearly dictates otherwise.
The present application is a continuation-in-part of U.S. application Ser. No. 11/736,537 filed Apr. 17, 2007 published as US2008/0262532 now U.S. Pat. No. 8,512,352.
Number | Name | Date | Kind |
---|---|---|---|
2918919 | Wallace | Dec 1959 | A |
2943626 | Dormia | Jul 1960 | A |
3996938 | Clark | Dec 1976 | A |
4347846 | Dormia | Sep 1982 | A |
4611594 | Grayhack et al. | Sep 1986 | A |
4699147 | Chilson et al. | Oct 1987 | A |
4790812 | Hawkins, Jr. et al. | Dec 1988 | A |
4807626 | McGirr | Feb 1989 | A |
4832055 | Palestrant | May 1989 | A |
4873978 | Ginsburg | Oct 1989 | A |
4969891 | Gewertz | Nov 1990 | A |
5057114 | Wittich et al. | Oct 1991 | A |
5059178 | Ya | Oct 1991 | A |
5102415 | Guenther et al. | Apr 1992 | A |
5147400 | Kaplan et al. | Sep 1992 | A |
5152777 | Goldberg et al. | Oct 1992 | A |
5192286 | Phan et al. | Mar 1993 | A |
5300086 | Gory et al. | Apr 1994 | A |
5443478 | Purdy | Aug 1995 | A |
5458375 | Anspach et al. | Oct 1995 | A |
5496330 | Bates et al. | Mar 1996 | A |
5509900 | Kirkman | Apr 1996 | A |
5653684 | Laptewicz et al. | Aug 1997 | A |
5658296 | Bates et al. | Aug 1997 | A |
5709704 | Nott et al. | Jan 1998 | A |
5733302 | Myler et al. | Mar 1998 | A |
5741325 | Chaikof et al. | Apr 1998 | A |
5792156 | Peroe | Aug 1998 | A |
5827324 | Cassell et al. | Oct 1998 | A |
5846251 | Hart | Dec 1998 | A |
5895398 | Wensel et al. | Apr 1999 | A |
5947995 | Samuels | Sep 1999 | A |
5968090 | Ratcliff et al. | Oct 1999 | A |
5971938 | Hart et al. | Oct 1999 | A |
5972019 | Engelson et al. | Oct 1999 | A |
6001118 | Daniel et al. | Dec 1999 | A |
6033394 | Vidlund et al. | Mar 2000 | A |
6053932 | Daniel et al. | Apr 2000 | A |
6066149 | Samson et al. | May 2000 | A |
6066158 | Engelson et al. | May 2000 | A |
6096053 | Bates | Aug 2000 | A |
6099534 | Bates et al. | Aug 2000 | A |
6159220 | Gobron et al. | Dec 2000 | A |
6165200 | Tsugita et al. | Dec 2000 | A |
6168603 | Leslie et al. | Jan 2001 | B1 |
6174318 | Bates et al. | Jan 2001 | B1 |
6190394 | Lind et al. | Feb 2001 | B1 |
6217609 | Haverkost | Apr 2001 | B1 |
6221006 | Dubrul et al. | Apr 2001 | B1 |
6245089 | Daniel et al. | Jun 2001 | B1 |
6248113 | Fina | Jun 2001 | B1 |
6264664 | Avellanet | Jul 2001 | B1 |
6302895 | Gobron et al. | Oct 2001 | B1 |
6309399 | Barbut et al. | Oct 2001 | B1 |
6348056 | Bates et al. | Feb 2002 | B1 |
6350266 | White et al. | Feb 2002 | B1 |
6364895 | Greenhalgh | Apr 2002 | B1 |
6371971 | Tsugita et al. | Apr 2002 | B1 |
6383195 | Richard | May 2002 | B1 |
6383196 | Leslie et al. | May 2002 | B1 |
6402771 | Palmer et al. | Jun 2002 | B1 |
6409750 | Hyodoh et al. | Jun 2002 | B1 |
6416505 | Fleischman et al. | Jul 2002 | B1 |
6425909 | Dieck et al. | Jul 2002 | B1 |
6436112 | Wensel et al. | Aug 2002 | B2 |
6443972 | Bosma et al. | Sep 2002 | B1 |
6458139 | Palmer et al. | Oct 2002 | B1 |
6485497 | Wensel et al. | Nov 2002 | B2 |
6494884 | Gifford, III et al. | Dec 2002 | B2 |
6506204 | Mazzocchi | Jan 2003 | B2 |
6514273 | Voss et al. | Feb 2003 | B1 |
6530935 | Wensel et al. | Mar 2003 | B2 |
6540657 | Cross, III et al. | Apr 2003 | B2 |
6551342 | Shen et al. | Apr 2003 | B1 |
6575997 | Palmer et al. | Jun 2003 | B1 |
6585753 | Eder et al. | Jul 2003 | B2 |
6592605 | Lenker et al. | Jul 2003 | B2 |
6592607 | Palmer et al. | Jul 2003 | B1 |
6602271 | Adams et al. | Aug 2003 | B2 |
6605102 | Mazzocchi et al. | Aug 2003 | B1 |
6610077 | Hancock et al. | Aug 2003 | B1 |
6616679 | Khosravi et al. | Sep 2003 | B1 |
6620148 | Tsugita | Sep 2003 | B1 |
6635068 | Dubrul et al. | Oct 2003 | B1 |
6636758 | Sanchez et al. | Oct 2003 | B2 |
6638245 | Miller et al. | Oct 2003 | B2 |
6641590 | Palmer et al. | Nov 2003 | B1 |
6645199 | Jenkins et al. | Nov 2003 | B1 |
6652505 | Tsugita | Nov 2003 | B1 |
6652548 | Evans et al. | Nov 2003 | B2 |
6660021 | Palmer et al. | Dec 2003 | B1 |
6663650 | Sepetka et al. | Dec 2003 | B2 |
6673042 | Samson et al. | Jan 2004 | B1 |
6679893 | Tran | Jan 2004 | B1 |
6685738 | Chouinard et al. | Feb 2004 | B2 |
6692508 | Wensel et al. | Feb 2004 | B2 |
6692509 | Wensel et al. | Feb 2004 | B2 |
6695858 | Dubrul et al. | Feb 2004 | B1 |
6702782 | Miller et al. | Mar 2004 | B2 |
6730104 | Sepetka et al. | May 2004 | B1 |
6745080 | Koblish | Jun 2004 | B2 |
6746468 | Sepetka et al. | Jun 2004 | B1 |
6749619 | Ouriel et al. | Jun 2004 | B2 |
6755813 | Ouriel et al. | Jun 2004 | B2 |
6800080 | Bates | Oct 2004 | B1 |
6824545 | Sepetka et al. | Nov 2004 | B2 |
6872211 | White et al. | Mar 2005 | B2 |
6872216 | Daniel et al. | Mar 2005 | B2 |
6890341 | Dieck et al. | May 2005 | B2 |
6893431 | Naimark et al. | May 2005 | B2 |
6905503 | Gifford, III et al. | Jun 2005 | B2 |
6913612 | Palmer et al. | Jul 2005 | B2 |
6936059 | Belef | Aug 2005 | B2 |
6939362 | Boyle et al. | Sep 2005 | B2 |
6945977 | Demarais et al. | Sep 2005 | B2 |
6953465 | Dieck et al. | Oct 2005 | B2 |
6964672 | Brady et al. | Nov 2005 | B2 |
7004955 | Shen et al. | Feb 2006 | B2 |
7004956 | Palmer et al. | Feb 2006 | B2 |
7037320 | Brady et al. | May 2006 | B2 |
7058456 | Pierce | Jun 2006 | B2 |
7097653 | Freudenthal et al. | Aug 2006 | B2 |
7101380 | Khachin et al. | Sep 2006 | B2 |
7169165 | Belef et al. | Jan 2007 | B2 |
7179273 | Palmer et al. | Feb 2007 | B1 |
7182771 | Houser et al. | Feb 2007 | B1 |
7235061 | Tsugita | Jun 2007 | B2 |
7534252 | Sepetka et al. | May 2009 | B2 |
8105333 | Sepetka et al. | Jan 2012 | B2 |
20010041909 | Tsugita et al. | Nov 2001 | A1 |
20010044634 | Don et al. | Nov 2001 | A1 |
20010051810 | Dubrul et al. | Dec 2001 | A1 |
20020002396 | Fulkerson | Jan 2002 | A1 |
20020004667 | Adams et al. | Jan 2002 | A1 |
20020026211 | Khosravi et al. | Feb 2002 | A1 |
20020058904 | Boock et al. | May 2002 | A1 |
20020062135 | Mazzocchi | May 2002 | A1 |
20020072764 | Sepetka et al. | Jun 2002 | A1 |
20020082558 | Samson et al. | Jun 2002 | A1 |
20020123765 | Sepetka et al. | Sep 2002 | A1 |
20020151928 | Leslie et al. | Oct 2002 | A1 |
20020188314 | Anderson et al. | Dec 2002 | A1 |
20020193825 | McGuckin et al. | Dec 2002 | A1 |
20030004542 | Wensel et al. | Jan 2003 | A1 |
20030023265 | Forber | Jan 2003 | A1 |
20030040771 | Hyodoh et al. | Feb 2003 | A1 |
20030050663 | Khachin et al. | Mar 2003 | A1 |
20030060782 | Bose et al. | Mar 2003 | A1 |
20030093087 | Jones et al. | May 2003 | A1 |
20030144687 | Brady et al. | Jul 2003 | A1 |
20030153935 | Mialhe | Aug 2003 | A1 |
20030195556 | Stack et al. | Oct 2003 | A1 |
20030195616 | Pinchasik et al. | Oct 2003 | A1 |
20040068288 | Palmer et al. | Apr 2004 | A1 |
20040073243 | Sepetka et al. | Apr 2004 | A1 |
20040079429 | Miller et al. | Apr 2004 | A1 |
20040133232 | Rosenbluth et al. | Jul 2004 | A1 |
20040138692 | Phung et al. | Jul 2004 | A1 |
20040153025 | Seifert et al. | Aug 2004 | A1 |
20040153118 | Clubb et al. | Aug 2004 | A1 |
20040172056 | Guterman et al. | Sep 2004 | A1 |
20040199201 | Kellett et al. | Oct 2004 | A1 |
20040199243 | Yodfat | Oct 2004 | A1 |
20040210116 | Nakao | Oct 2004 | A1 |
20040267301 | Boylan et al. | Dec 2004 | A1 |
20050004594 | Nool et al. | Jan 2005 | A1 |
20050033348 | Sepetka et al. | Feb 2005 | A1 |
20050038447 | Huffmaster | Feb 2005 | A1 |
20050043680 | Segal et al. | Feb 2005 | A1 |
20050043756 | Lavelle | Feb 2005 | A1 |
20050049619 | Sepetka et al. | Mar 2005 | A1 |
20050055033 | Leslie et al. | Mar 2005 | A1 |
20050055047 | Greenhalgh | Mar 2005 | A1 |
20050059995 | Sepetka et al. | Mar 2005 | A1 |
20050080356 | Dapolito et al. | Apr 2005 | A1 |
20050085826 | Nair et al. | Apr 2005 | A1 |
20050085847 | Galdonik et al. | Apr 2005 | A1 |
20050085849 | Sepetka et al. | Apr 2005 | A1 |
20050090857 | Kusleika et al. | Apr 2005 | A1 |
20050090858 | Pavlovic | Apr 2005 | A1 |
20050125024 | Sepetka et al. | Jun 2005 | A1 |
20050131450 | Nicholson et al. | Jun 2005 | A1 |
20050171566 | Kanamaru | Aug 2005 | A1 |
20050203571 | Mazzocchi et al. | Sep 2005 | A1 |
20050209609 | Wallace | Sep 2005 | A1 |
20050216030 | Sepetka et al. | Sep 2005 | A1 |
20050216050 | Sepetka et al. | Sep 2005 | A1 |
20050234501 | Barone | Oct 2005 | A1 |
20050234505 | Diaz et al. | Oct 2005 | A1 |
20050277978 | Greenhalgh | Dec 2005 | A1 |
20050283166 | Greenhalgh | Dec 2005 | A1 |
20050283186 | Berrada et al. | Dec 2005 | A1 |
20060004404 | Khachin | Jan 2006 | A1 |
20060009784 | Behl et al. | Jan 2006 | A1 |
20060047286 | West | Mar 2006 | A1 |
20060058836 | Bose et al. | Mar 2006 | A1 |
20060058837 | Bose et al. | Mar 2006 | A1 |
20060058838 | Bose et al. | Mar 2006 | A1 |
20060095070 | Gilson et al. | May 2006 | A1 |
20060129166 | Lavelle | Jun 2006 | A1 |
20060129180 | Tsugita et al. | Jun 2006 | A1 |
20060155305 | Freudenthal et al. | Jul 2006 | A1 |
20060190070 | Dieck | Aug 2006 | A1 |
20060195137 | Sepetka et al. | Aug 2006 | A1 |
20060229638 | Abrams et al. | Oct 2006 | A1 |
20060253145 | Lucas | Nov 2006 | A1 |
20060276805 | Yu | Dec 2006 | A1 |
20060282111 | Morsi | Dec 2006 | A1 |
20070112374 | Paul et al. | May 2007 | A1 |
20070118165 | DeMello | May 2007 | A1 |
20070185500 | Martin et al. | Aug 2007 | A1 |
20070185501 | Martin et al. | Aug 2007 | A1 |
20070197103 | Martin et al. | Aug 2007 | A1 |
20070198029 | Martin et al. | Aug 2007 | A1 |
20070198030 | Martin et al. | Aug 2007 | A1 |
20070225749 | Martin et al. | Sep 2007 | A1 |
20070265656 | Amplatz et al. | Nov 2007 | A1 |
20080109031 | Sepetka et al. | May 2008 | A1 |
20080183198 | Sepetka et al. | Jul 2008 | A1 |
20080188885 | Sepetka et al. | Aug 2008 | A1 |
20080262528 | Martin | Oct 2008 | A1 |
20080262532 | Martin | Oct 2008 | A1 |
20090192518 | Golden et al. | Jul 2009 | A1 |
20090287291 | Becking et al. | Nov 2009 | A1 |
20090299393 | Martin et al. | Dec 2009 | A1 |
20100076452 | Sepetka et al. | Mar 2010 | A1 |
20100185210 | Hauser et al. | Jul 2010 | A1 |
20110166586 | Sepetka et al. | Jul 2011 | A1 |
20110288572 | Martin | Nov 2011 | A1 |
20120143230 | Sepetka et al. | Jun 2012 | A1 |
20120197285 | Martin et al. | Aug 2012 | A1 |
Number | Date | Country |
---|---|---|
1640505 | Jul 2005 | CN |
3501707 | Jul 1986 | DE |
1312314 | May 2003 | EP |
1312314 | Oct 2005 | EP |
11-47140 | Jun 1989 | JP |
62-49841 | Sep 1994 | JP |
2002-537943 | Nov 2002 | JP |
2007-522881 | Aug 2007 | JP |
2007-252951 | Oct 2007 | JP |
2008-539958 | Nov 2008 | JP |
WO 2000053120 | May 1994 | WO |
WO 1996001591 | Jan 1996 | WO |
WO 1996019941 | Jul 1996 | WO |
WO 1997027808 | Aug 1997 | WO |
WO 1997027893 | Aug 1997 | WO |
WO 1998003120 | Jan 1998 | WO |
WO 0072909 | Dec 2000 | WO |
WO 0132254 | May 2001 | WO |
WO 0167967 | Sep 2001 | WO |
WO 0202162 | Jan 2002 | WO |
WO 0202162 | Jan 2002 | WO |
WO 0228291 | Apr 2002 | WO |
WO 0228291 | Apr 2002 | WO |
WO 03000334 | Jan 2003 | WO |
WO 03061730 | Jul 2003 | WO |
WO 03061730 | Jul 2003 | WO |
WO 03089039 | Oct 2003 | WO |
WO 06031410 | Mar 2006 | WO |
WO 06031410 | Mar 2006 | WO |
WO 2006122076 | Nov 2006 | WO |
WO 2007092820 | Aug 2007 | WO |
WO 2008131116 | Oct 2008 | WO |
2009017827 | Feb 2009 | WO |
WO 2009034456 | Mar 2009 | WO |
WO 2009086482 | Jul 2009 | WO |
WO 2011091383 | Jul 2011 | WO |
2011130579 | Oct 2011 | WO |
WO 2012009675 | Jan 2012 | WO |
2012154782 | Nov 2012 | WO |
WO 2012162437 | Nov 2012 | WO |
Entry |
---|
U.S. Appl. No. 11/671,450, filed Feb. 5, 2007 in the name of Martin et al., Non-final Office Action dated Jan. 26, 2009. |
International Patent Application No. PCT/US2007/061634 filed Feb. 5, 2007 in the name of Martin et al., International Search Report and Written Opinion dated Nov. 29, 2007. |
International Patent Application No. PCT/US2008/060653 filed Apr. 17, 2008 in the name of Martin, International Search Report and Written Opinion dated Aug. 7, 2008. |
International Patent Application No. PCT/IB2008/002373 filed Sep. 12, 2008 in the name of Martin et al., International Search Report and Written Opinion dated Jun. 3, 2009. |
International Patent Application No. PCT/US2008/088371 filed Dec. 26, 2008 in the name of Martin et al., International Search Report and Written Opinion dated Apr. 16, 2009. |
European Patent Application No. 08746132.3 filed Apr. 17, 2008 in the name of Martin, Supplemental Search Report and Written Opinion dated Apr. 6, 2011. |
PCT International Patent Application No. PCT/US2010/026571 filed Mar. 8, 2010 in the name of Martin, PCT International Search Report and Written Opinion dated Jul. 9, 2010. |
U.S. Appl. No. 11/671,450, filed Feb. 5, 2007, in the name of Martin et al. Final Office Action dated Oct. 5, 2009. |
U.S. Appl. No. 11/671,450, filed Feb. 5, 2007, in the name of Martin et al. Non-final Office Action dated Nov. 17, 2010. |
U.S. Appl. No. 11/684,521, filed Mar. 9, 2007, in the name of Martin et al., Non-Final Office Action dated Sep. 28, 2009. |
U.S. Appl. No. 11/684,521, filed Mar. 9, 2007, in the name of Martin et al., Non-Final Office Action dated Apr. 29, 2010. |
U.S. Appl. No. 11/684,521, filed Mar. 9, 2007, in the name of Martin et al., Final Office Action dated Nov. 5, 2010. |
U.S. Appl. No. 11/684,521, filed Mar. 9, 2007, in the name of Martin et al., Non-final Office Action dated May 26, 2011. |
U.S. Appl. No. 11/684,535, filed Oct. 13, 2009, in the name of Martin et al., Non-Final Office Action dated Oct. 13, 2009. |
U.S. Appl. No. 11/684,535, filed Mar. 9. 2007, in the name of Martin et al., Non-Final Office Action dated May 13, 2010. |
U.S. Appl. No. 11/684,535, filed Mar. 9, 2007, in the name of Martin et al., Final Office Action dated Nov. 22, 2010. |
U.S. Appl. No. 11/684,541, filed Mar. 9, 2007, in the name of Martin et al., Non-Final Office Action dated Oct. 15, 2009. |
U.S. Appl. No. 11/684,541, filed Mar. 9, 2007, in the name of Martin et al., Non-Final Office Action dated May 11, 2010. |
U.S. Appl. No. 11/684,541, filed Mar. 9, 2007, in the name of Martin et al., Final Office Action dated Nov. 22, 2010. |
U.S. Appl. No. 11/684,546, filed Mar. 9, 2007, in the name of Martin et al., Non-Final Office Action dated Oct. 13, 2009. |
U.S. Appl. No. 11/684,546, filed Mar. 9, 2007, in the name of Martin et al., Non-Final Office Action dated May 11, 2010. |
U.S. Appl. No. 11/684,546, filed Mar. 9, 2007, in the name of Martin et al., Final Office Action dated Nov. 22, 2010. |
U.S. Appl. No. 11/684,982, filed Nov. 13, 2009, in the name of Martin et al., Non-Final Office Action dated Nov. 13, 2009. |
U.S. Appl. No. 11/684,982, filed Mar. 12, 2007, in the name of Martin et al., Non-Final Office Action dated Jun. 15, 2010. |
U.S. Appl. No. 11/684,982, filed Mar. 12, 2007, in the name of Martin et al., Final Office Action dated Feb. 25, 2011. |
U.S. Appl. No. 11/736,526, filed Apr. 17, 2007, in the name of Martin et al., Non-Final Office Action dated Jun. 24, 2010. |
U.S. Appl. No. 11/736,526, filed Apr. 17, 2007, in the name of Martin et al., Final Office Action dated Mar. 16, 2011. |
U.S. Appl. No. 11/736,537, filed Apr. 17, 2007, in the name of Martin et al., Non-Final Office Action dated Jun. 29, 2010. |
U.S. Appl. No. 11/736,537, filed Apr. 17, 2007, in the name of Martin et al., Final Office Action dated Mar. 17, 2011. |
Number | Date | Country | |
---|---|---|---|
20090069828 A1 | Mar 2009 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11736537 | Apr 2007 | US |
Child | 11852975 | US |